Core Viewpoint - The Chinese traditional medicine industry is experiencing significant growth driven by policy support and increasing health demands, with a focus on balancing tradition and innovation [1] Group 1: Company Strategy - Jilin Aodong Pharmaceutical Group Co., Ltd. adopts a dual-driven strategy of "medicine health + financial capital" to modernize traditional Chinese medicine [1] - The company has established a robust capital collaborative network, holding 20.11% of Guangfa Securities and being a major shareholder in several pharmaceutical companies, which supports its main business [2][3] - Financial returns from investments in Guangfa Securities contributed 12.43 billion yuan and 17.49 billion yuan in 2023 and 2024 respectively, providing continuous financial support for the pharmaceutical business [3] Group 2: Financial Empowerment - The financial layout allows Jilin Aodong to maintain stable and abundant returns, which are reinvested into the pharmaceutical sector to alleviate the high risks and long cycles of research and development [3] - The company emphasizes a principle of "main business first, financial empowerment," ensuring that financial gains are directed back to support the core pharmaceutical operations [3] Group 3: Technological Innovation - Jilin Aodong places technological innovation at the core of its strategy, focusing on the research of key raw materials and advancing in fields like anti-aging and regenerative medicine [5] - The company has developed a closed-loop industrial chain around the breeding, processing, and quality control of deer antler, ensuring the quality and traceability of raw materials [5][6] - The implementation of modern technology in traditional practices is seen as essential for unlocking the core value of traditional Chinese medicine [5][6] Group 4: Industry Development - The modernization of traditional Chinese medicine is supported by national policies aimed at enhancing quality, digital transformation, and new drug development [4] - Jilin Aodong aims to reshape production factors through technological innovation, transitioning from resource-dependent to innovation-driven models [6] - The company is committed to continuous investment in research and development, enhancing its intelligent layout across the entire industrial chain, and maintaining its heritage as a time-honored brand [7]

Core Viewpoint - The Chinese traditional medicine industry is experiencing significant growth driven by policy support and increasing health demands, with a focus on balancing heritage and innovation [1] Group 1: Company Strategy - Jilin Aodong Pharmaceutical Group Co., Ltd. adopts a dual-driven strategy of "pharmaceutical health + financial capital" to modernize traditional Chinese medicine [1] - The company has established a robust capital collaborative network, holding 20.11% of Guangfa Securities and being a major shareholder in several pharmaceutical companies, which supports its main business [2][3] Group 2: Financial Performance - In 2023 and 2024, the investment in Guangfa Securities is expected to contribute 1.243 billion and 1.749 billion yuan in revenue, respectively, with a total of 8.757 billion yuan in cash dividends provided to the company [3] - Financial returns are reinvested into the pharmaceutical business, alleviating the high risks and long cycles associated with research and development [3] Group 3: Technological Innovation - The modernization of traditional Chinese medicine relies on modern technology to unlock its core value, transitioning from "experience inheritance" to "scientific decoding" [4] - Jilin Aodong focuses on core material research and is actively involved in cutting-edge fields such as anti-aging and regenerative medicine [4][5] Group 4: Production and Quality Control - The company has developed a closed-loop industrial chain around the breeding, processing, and quality control of its core product, the Aodong deer antler [4][6] - Investments exceeding 46 million yuan have been made to upgrade disease prevention facilities and implement a digital quality control system across its standardized breeding bases [6] Group 5: Future Outlook - Jilin Aodong aims to deepen its dual-driven advantages and integrate new productive forces throughout its industrial development process, focusing on continuous investment in research and intelligent layout [7]

Core Viewpoint - The modernization of traditional Chinese medicine relies heavily on the quality of raw materials, with Jilin Aodong Pharmaceutical Group Co., Ltd. achieving significant milestones in the deer farming industry by becoming the first company in China to receive national certification for disease-free deer farming [1][2] Group 1: Company Achievements - Jilin Aodong's deer breeding base passed the national-level evaluation for Brucella and tuberculosis disease-free status, marking a significant advancement in safety standards for the deer farming industry [1] - The company has invested over 46 million yuan in upgrading disease prevention facilities and has established a comprehensive monitoring system for disease prevention [1] - Since 2021, Jilin Aodong has maintained a zero-positive rate for Brucella and tuberculosis through precise control measures [1] Group 2: Industry Practices - The company operates a GAP-standardized deer breeding base covering over 350 hectares in the Changbai Mountain core area, with a stock of nearly 3,000 deer [2] - Jilin Aodong adheres to traditional natural feeding methods, avoiding the use of premixed feed, and implements a closed-loop management system for deer antler raw materials, ensuring all quality resources remain within its own system [2] - The company has developed the first deer breed named after itself, "Aodong Sika Deer," ensuring the purity and quality traits of the raw materials [2] Group 3: Future Outlook - Jilin Aodong plans to continue strengthening raw material safety standards in alignment with the "Healthy China" strategy and the "14th Five-Year Plan," aiming to promote the standardization and high-end development of the deer industry in Jilin Province [2]